Oncology, answered.

Author affiliations: Penn Medicine, Flatiron Health

Abstract Number: 1583
Poster Session: Care Delivery/Models of Care
Poster Board: 501
Date and Time: May 30, 2026, 9-12 PM

External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1-high metastatic non-small cell lung cancer

 Author affiliations: Author affiliations: Emory University, Onc.AI, OhioHealth, Flatiron Health

Abstract Number: 2534
Poster Session: Developmental Therapeutics—Immunotherapy
Poster Board: 324
Date and Time: May 30, 2026, 1:30- 4:30 PM 

Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC)

Author affiliations: Flatiron Health

Abstract Number: 4600
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 79
Date and Time: May 31, 2026, 9-12 PM

Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era

Author affiliations: Flatiron Health

Abstract Number: 8083
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 557
Date and Time: May 31, 2026, 9-12 PM

Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer

Author affiliations: Jazz Pharmaceuticals, Nebraska Western Iowa Health Care System/University of Nebraska Medical Center, Flatiron Health

Abstract Number: 8093
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 567
Date and Time: May 31, 2026, 9-12 PM

A risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases

Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health

Abstract Number: 11138
Poster Session: Quality Care/Health Services Research Track
Poster Board: 121
Date and Time: June 1, 2026, 9-12pm

Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes

Author affiliations: Flatiron Health

Abstract Number: 5566
Poster Session: Gynecologic Cancer
Poster Board: 232
Date and Time: June 1, 2026, 9-12pm

Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)

Author affiliations: Gilead Sciences, IQVIA, Flatiron Health

Abstract Number: 1025
Poster Session: Breast Cancer—Metastatic
Poster Board: 139
Date and Time: June 1, 2026, 1:30-4:30 PM

RW post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with HR+/HER2− metastatic breast cancer (MBC) in US.

Author affiliations: University of Illinois Cancer Center, Wake Forest University/Florida Cancer Specialists, Harvard Medical School, University of Kansas Medical Center, Dana-Farber Cancer Institute, Novartis, City of Hope Comprehensive Cancer Center, Flatiron Health

Abstract Number: 1073
Poster Session: Breast Cancer—Metastatic
Poster Board: 187
Date and Time: June 1, 2026, 1:30-4:30 PM

Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease

Author affiliations: Flatiron Health

Abstract Number: 547
Poster Session: Cancer—Local/Regional/Adjuvant
Poster Board: 32
Date and Time: June 1, 2026, 1:30-4:30 PM